Lymphangiogenesis driven by VEGF-C reshapes tumor immune landscape and enables tumor eradication by viral immunotherapy
Authors:
- Ruben Fernandez-RodriguezRFRuben Fernandez-Rodriguez
- Sara Cuadrado-CastanoSCSara Cuadrado-Castano
- Andrew EdwardsAEAndrew Edwards
- Anita RogicARAnita Rogic
- Yonina BykovYBYonina Bykov
- Ignacio MenaIMIgnacio Mena
- Noelia Dasilva-FreireNDNoelia Dasilva-Freire
- Alice O KamphorstAKAlice O Kamphorst
- Rosa KarlicRKRosa Karlic
- Amir HorowitzAHAmir Horowitz
- Adolfo García-SastreAGAdolfo García-Sastre
- Mihaela SkobeMSMihaela Skobe
Preprint
Abstract
Vascular Endothelial Growth Factor C (VEGF-C) is a key lymphangiogenic growth factor expressed by many types of cancer. Here, we investigated the effects of tumor-derived VEGF-C on the therapeutic efficacy of oncolytic virotherapy with avian paramyxoviruses APMV-1 (NDV) and AMPV-4. Treatment of B16F10 tumors not expressing VEGF-C with either virus led to tumor growth delay, and complete responses were rare. In contrast, when tumors expressed VEGF-C, viral therapy led to complete remission and long-term immunological memory in most mice. Upon re-challenge, most mice remained tumor- and metastasis-free for over 18 months, indicating durable immunity. VEGF-C induced tumor lymphangiogenesis, which correlated with high CD8 + and CD4 + T-cell densities in proximity of lymphatic vessels. Spectral flow cytometry revealed distinct changes in the composition and activation of CD8 + , CD4 + T cells and NK cells associated with complete remission. In responders, tumors were highly enriched in CD8 + CD25 + PD-1 + effector T cells. Composition of T cells was altered in sentinel and in contralateral lymph nodes, indicating a systemic immune response. Taken together, these data demonstrate VEGF-C-induced changes in tumor immune landscape which are critical for achieving complete response and support combining VEGF-C with APMV virotherapy as a novel highly effective strategy for cancer treatment.Keywords
Funding Information
- Pershing Square Philantropies
- Tisch Cancer Institute at Mount Sinai (P30 CA196521)
This publication has 64 references indexed in Scilit:
- Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation2020
- Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanomaEBioMedicine, 2019
- Significance and Molecular Regulation of Lymphangiogenesis in Cancer2019
- Exploiting lymphatic vessels for immunomodulation: Rationale, opportunities, and challengesAdvanced Drug Delivery Reviews, 2017
- Talimogene Laherparepvec (T-VEC) and Other Oncolytic Viruses for the Treatment of MelanomaAmerican Journal of Clinical Dermatology, 2016
- A Distinct Gene Module for Dysfunction Uncoupled from Activation in Tumor-Infiltrating T CellsCell, 2016
- Expansion and Activation of CD103+ Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF InhibitionImmunity, 2016
- VEGF-C Promotes Immune Tolerance in B16 Melanomas and Cross-Presentation of Tumor Antigen by Lymph Node LymphaticsCell Reports, 2012
- Therapeutic effects of a fusogenic newcastle disease virus in treating head and neck cancerHead & Neck, 2010
- A novel vascular endothelial growth factor, VEGF‐C, is a ligand for the Flt4 (VEGFR‐3) and KDR (VEGFR‐2) receptor tyrosine kinases.The EMBO Journal, 1996